The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hutchinson clearly screwed the investment case for a while here. The problem being that they have now created a big overhang going forward for the rest of their stake which is over 52%. They are only locked in for 3 months. I'm surprised they haven't said they will stay invested for 12 months but with HK listing a possibility sometimes later in the year, maybe that's when they want to sell more. Hard to see the HK listing going ahead at any half decent price now .I'd expect the shares here to keep drifting off even after the MS shares have been placed.
Matt ,
I wondered when you would surface. As per my post on the 4th December , I sold all my HCM at levels well above 50 quid and made close to a million quid so I think my timing on this particular investment was spot on . Good enough for you ??
Clearly bad news the warrants were not exercised . Since the share price was nowhere near 35p, there was no hope of the warrants being exercised .
Sadly that meant that SAVP were strapped of cash.Hence the awful placing at 28p which has dampened the share price and sentiment when it was trading comfortably above 30p. That also clarifies why Niger tests have been delayed despite the nonsense spouted by AK to the contrary. its all about cashflow nothing else.
The conclusion of the Seven transaction is paramount to allow the company to get hold of funds as well as confirming bright future of what looks a terrific acquistion . until then we tread water imo.
I think getting a farm in partner for Niger is absolutely paramount asap to ensure that opportunity can be developed .
As per the RNS today , Ashmore down to 2.849% . Clearly they have been sellers for a while now. and have 25million left.
The savp website indicated Ashmore had about 6.51% on 1st Feb .Seems like they were wrong as the RNS's released prior to that date have indicated.
nen2319, I think you are being a bit simplistic in your assumptions. You can't create a big company without issuing shares or doing deals. Yes , it pushes targets down the road but if acquistions are clearly accretive, then it's for the greater good.
Savp clearly have to deliver on their assumptions of cashflow and other targets and that will make the investment case take a lot longer than perhaps some are envisaging .
I'm glad you have 6 figures invested in savp and I'm sure it will pay off. I have the same invested in it and nothing to date has worried me at all.
I invested in HCM for the past 3 years and made close to a million quid before selling in December . I started posting on the LSE HCM board around that time and continued ever since till I posted my selling out right near the peak. Investments take time to mature as witnessed by Zengas's Cove.
Sadly, talk of hero worship and mockery of targets without any substantive comments to back that up do you no credit. Research, research , research !
As for bonus performance and share price performance, AK has a lot more skin in the game than you or me. So far he has delivered in my view. I'm more than happy with the progress even though so far I'm losing on my overall investment in SAVP at an average of 33p.
! million shares gone through at 33p
nice to see Hambro buying. Pity we can never work out who is selling.
I've added another 100k this am now the big AT seller has cleared.
I think confidence has been shaken by the recent RNS .There were clearly at least 2 bits of negative news and CH's confidence in those data was misplaced. I've listened to presentations over and over again and so the epidemiology news was a shocker imo.
I originally thought on the release of the rns the share price could fall to close to 30 quid esp. in a poor market. I can't say I'm remotely tempted to buy back at 35 quid and I think the slide will continue .Saying all that , all is to play for for HCM , but they really need some good data readouts to restore confidence imo.
I was very lucky that the MSCI volume allowed me to sell my 35k shares but with the roller coaster this share has had since announcing the Nasdaq ipo , I think I deserved my luck on this occasion.
davey, tbh posted as I was hoping you might sell a few in the face of these tough markets after that huge spike. I can 't say i'm tempted to buy back in anywhere near this price in the absence of some news. Saying that, its easy to become bearish when markets are so weak. Personally, I would take profits even at this level .
It will be interesting to see what price hcm finishes at in the US tonight . If it does induce a big spike , I would def sell your adr's tonight in the auction. The Nasdaq biotech inclusion is around 50/50 in terms of price moves so hard to be sure. Good Luck.
I think the fall has not been too bad so far so perhaps it may hold up although I doubt it. Personally got my brother to sell out totally this am . I don't see the risk in holding them for now short term.
The news was poor on MES....very clear.
Lily not really taking up Fruq option in China is a negative but large'y expected. They may not take up their worldwide rights on FRUQ but again that would be expected.
The increased investment is fully expected imo.
Azn doing more trials with savo is good news. although I didn't think the savo trial data was that compelling (bwtfdik).
A few chinks in HCM recently but not terminal at all to the investment case longer term.
There will be very big volume tomorrow in the US on HCM but not necessarily indicating an obvious spike either way that could be relied upon. Don't read anything into that volume.
Bon chance.
Since I've been a long time bull on hcm, it would be remiss of me not say I have closed all my HCM in the past 10days. As some will know , it was a very big position (Matt, I tend to have the last laugh as I said at the time when you mocked my high buying price!!) . I like telling people I have bought and sold as early as possible and not a month after as is so often the case. Happily the share price is very strong still.
My reasons for selling are certainly not specific to the investment case for HCM . I think they are due a lot of big news this month and the share price could move much higher. But as we know from the recent fruquintinib news , nothing is guaranteed with pharma stocks. So that was a wake up call for me.
The liquidity of the MSCI gave me a chance to close my position so I took it . It was more for good housekeeping to protect some profits in this uncertain market .
I shall be buying back into HCM but not in the same size as previously. I wish holders all the best luck , esp. davey, whose posts have been superb.
Add to that,
3. 2nd Line PFS data for Savo/tagrisso due to be released by end 2018. CH has said this data is very encouraging.
4.Likely inclusion into Nasdaq Biotech index. Should be announced early December imo. Entry 21st December.
So yes, loads of news due!!
MSCI CHINA INDEX Additions Deletions 360 SECURITY A (HK-C) CHINA INTL MARINE CONT H CHINA HONGQIAO GROUP CHINA NUCLEAR A (HK-C) CHINA INV FUND INTL (CN) CHONG SING HLDGS FINTECH CHINA ORIENTAL GROUP CHONGQING CHANGAN AUTO B CHINA SHIPB IND A (HK-C) COSCO SHIPPING DEV CO H DONGFANG ELECTR A (HK-C) DR PENG TELECOM A (HK-C) HUTCHISON CHINA ADR FANG HOLDINGS ADR MAANSHAN IRON&STEEL H GCL POLY ENERGY OPPEIN HOME GRP A (HK-C) SDIC CAPITAL CO A (HK-C) S F HOLDING A (HK-C) SKYWORTH DIGITAL HLDGS YIHAI INTL HLDG ZHEJIANG SEMIR A (HK-C)
davey , do hcm have a china listing ? I was surprised to read that hcm are being added to the MSCI china index on the 30th November ? There will presumably be good buying of it as funds may need to buy if they haven't already so.
The share price rose 20% prior to this news so no surprise at all by this fall. In fact , I'd go as far to say, the share price has held up pretty well today so far!! Fingers crossed it stays here at least when the Us trades it today.